DK2137539T3 - Amolorid følsomme calciumkanaler forbundet med paniklidelser - Google Patents
Amolorid følsomme calciumkanaler forbundet med paniklidelserInfo
- Publication number
- DK2137539T3 DK2137539T3 DK08715633.7T DK08715633T DK2137539T3 DK 2137539 T3 DK2137539 T3 DK 2137539T3 DK 08715633 T DK08715633 T DK 08715633T DK 2137539 T3 DK2137539 T3 DK 2137539T3
- Authority
- DK
- Denmark
- Prior art keywords
- panic disorder
- polymorphisms
- amoloride
- calcium channels
- channels associated
- Prior art date
Links
- 208000019906 panic disease Diseases 0.000 title abstract 6
- 108090000312 Calcium Channels Proteins 0.000 title 1
- 102000003922 Calcium Channels Human genes 0.000 title 1
- 102000004310 Ion Channels Human genes 0.000 abstract 3
- 108090000862 Ion Channels Proteins 0.000 abstract 3
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 abstract 3
- 229960002576 amiloride Drugs 0.000 abstract 3
- 102000054765 polymorphisms of proteins Human genes 0.000 abstract 3
- 230000001413 cellular effect Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- WCSPDMCSKYUFBX-ZJZGAYNASA-N (2s)-n-[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]-2-[[(2s)-2-[[(2s)-2-amino-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-(diaminomethylideneamino)pentanamide Chemical compound C([C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C1=CC=CC=C1 WCSPDMCSKYUFBX-ZJZGAYNASA-N 0.000 abstract 1
- 108020005345 3' Untranslated Regions Proteins 0.000 abstract 1
- 101800000164 FMRF-amide Proteins 0.000 abstract 1
- 101000623875 Grammostola rosea M-theraphotoxin-Gr1a Proteins 0.000 abstract 1
- WVDNTWXIIKNMHY-UHFFFAOYSA-N GsMTx4 Chemical compound O=C1NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CCCCN)C(=O)NC(C(NC(CC(N)=O)C(=O)N2CCCC2C(=O)NC(CC(N)=O)C(=O)NC(CC(O)=O)C(=O)NC(CC(O)=O)C(=O)NC(CCCCN)C(=O)NC(CSSCC(NC(=O)C(CC(C)C)NC(=O)C(CCCCN)NC(=O)C(CC=2C=CC=CC=2)NC(=O)C(CC(C)C)NC(=O)C(CCCCN)NC(=O)C(CO)NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CO)C(=O)NC(CC=3C=CC=CC=3)C(N)=O)C(=O)N3)=O)CSSCC2NC(=O)C(CCCCN)NC(=O)C(CC(C)C)NC(=O)C(CCCCN)NC(=O)C2CCCN2C(=O)C(CCCNC(N)=N)NC(=O)C3CSSCC(NC(=O)CN)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC1CC1=CC=CC=C1 WVDNTWXIIKNMHY-UHFFFAOYSA-N 0.000 abstract 1
- 101000901079 Homo sapiens Acid-sensing ion channel 2 Proteins 0.000 abstract 1
- 108091023045 Untranslated Region Proteins 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/301—Anxiety or phobic disorders
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Credit Cards Or The Like (AREA)
- Liquid Crystal Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200700519 | 2007-04-03 | ||
| PCT/DK2008/050080 WO2008119360A1 (en) | 2007-04-03 | 2008-04-03 | Amiloride sensitive sodium channels associated with panic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2137539T3 true DK2137539T3 (da) | 2011-01-24 |
Family
ID=38312417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08715633.7T DK2137539T3 (da) | 2007-04-03 | 2008-04-03 | Amolorid følsomme calciumkanaler forbundet med paniklidelser |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP2137539B1 (da) |
| AT (1) | ATE483985T1 (da) |
| DE (1) | DE602008002913D1 (da) |
| DK (1) | DK2137539T3 (da) |
| WO (1) | WO2008119360A1 (da) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9371383B2 (en) | 2012-01-31 | 2016-06-21 | Regeneron Pharmaceuticals, Inc. | Anti-ASIC1 antibodies and uses thereof |
| HUE042531T2 (hu) | 2012-01-31 | 2019-07-29 | Regeneron Pharma | ASIC1-ellenes antitestek és alkalmazásaik |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2304494A1 (en) * | 2000-04-20 | 2001-10-20 | Philippe Seguela | A novel heteromultimeric ion channel receptor and uses thereof |
| US20030186860A1 (en) * | 2002-03-29 | 2003-10-02 | Welsh Michael J. | Novel compositions and methods for modulating the acid-sensing ion channel (ASIC) |
-
2008
- 2008-04-03 EP EP08715633A patent/EP2137539B1/en not_active Not-in-force
- 2008-04-03 WO PCT/DK2008/050080 patent/WO2008119360A1/en not_active Ceased
- 2008-04-03 DE DE602008002913T patent/DE602008002913D1/de active Active
- 2008-04-03 DK DK08715633.7T patent/DK2137539T3/da active
- 2008-04-03 AT AT08715633T patent/ATE483985T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008119360A1 (en) | 2008-10-09 |
| DE602008002913D1 (de) | 2010-11-18 |
| EP2137539B1 (en) | 2010-10-06 |
| ATE483985T1 (de) | 2010-10-15 |
| EP2137539A1 (en) | 2009-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL301145I2 (nl) | Tirbanibulin | |
| EA200702048A1 (ru) | Фармакокинетически улучшенные соединения | |
| PH12018500045A1 (en) | Compositions and methods for treating and diagnosing asthma | |
| MX2007014616A (es) | Inhibidores de señalizacion del receptor del factor a de crecimiento endotelial vascular y del receptor del factor de crecimiento de hepatocitos. | |
| CY1117546T1 (el) | Eνωση διαμινο ετεροκυκλικου καρβοξαμιδιου | |
| EA201270184A1 (ru) | Лечение расстройств печени ингибиторами pi3k | |
| EA200702203A1 (ru) | Способы и нуклеиновые кислоты для анализов клеточных пролиферативных нарушений | |
| BRPI0513982A (pt) | inibidores de sinalização de receptor de vegf e receptor de hgf | |
| ATE446094T1 (de) | Mitotische kinesin-hemmer | |
| EA200901313A1 (ru) | Ингибиторы тирозинкиназы брутона | |
| TW200636075A (en) | Detection of nucleic acid variation by cleavage-amplification method | |
| IN2012DN02485A (da) | ||
| MY148468A (en) | Compounds and methods for kinase modulation, and indications therefor | |
| MX2009006688A (es) | Compuestos y metodos para modulacion de cinasas, e indicaciones para ello. | |
| WO2010036960A8 (en) | Methods for treating, diagnosing, and monitoring lupus | |
| EA200801046A1 (ru) | Неинвазивный способ выявления переходно-клеточной карциномы мочевого пузыря in vitro | |
| ATE461923T1 (de) | Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren | |
| WO2008106594A3 (en) | Inhibitors of nucleophosmin (npm) and methods for inducing apoptosis | |
| BRPI0508254A (pt) | métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos | |
| ATE540036T1 (de) | Heterocyclische derivate als ionenkanalmodulatoren | |
| WO2009073575A3 (en) | Methods for treating induced cellular proliferative disorders | |
| DE602005001192D1 (de) | Zusammensetzung und Verfahren zur Verbesserung der Wärmestabilität und der Witterungsstabilität von segementierten Polyurethanpolymeren | |
| DK2137539T3 (da) | Amolorid følsomme calciumkanaler forbundet med paniklidelser | |
| PT1529116E (pt) | Métodos para o tratamento da demência com base no genótipo da apo e | |
| MX2012001999A (es) | Uso de inhibidores nkg2d para tratar enfermedades cardiovasculares y metabolicas, tal como diabetes tipo 2. |